Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONCO PE: Rivaroxaban duration in cancer-associated PE
NCT04724460Phase 4Completed
- Start
- Feb 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rivaroxaban in pulmonary embolism (PE), venous thromboembolism (VTE). Started Feb 2021; status: completed.
02
Drugs
rivaroxaban
03
Conditions
pulmonary embolism (PE)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT04724460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04724460.